Search results
29 cze 2021 · The objective of this narrative review is to revise efficacy and safety data of the latest biologicals, small oral molecules and biosimilar drugs for the treatment of chronic plaque psoriasis at Phase III of clinical development.
7 lut 2024 · In this phase 2 dose-finding trial, we randomly assigned patients with moderate-to-severe plaque psoriasis to receive JNJ-77242113 at a dose of 25 mg once daily, 25 mg twice daily, 50 mg once...
FDA Approves BIMZELX® The first biologic targeting IL-17A and IL-17F is now approved for adults with moderate to severe plaque psoriasis. Read More
16 lut 2021 · It is the only biologic with data and FDA labeling specifically for genital plaque psoriasis. Also, ixekizumab is the only IL-17 agent that is FDA approved for treatment of plaque psoriasis down to the age of 6 years old.
25 sie 2022 · A number of over-the-counter (OTC) products are available to help treat symptoms of psoriasis. Learn about the most commonly used OTC products, and how they work to relieve symptoms.
1 wrz 2021 · Newer biologics such as secukinumab, ixekizumab, brodalumab and risankizumab were more favourable compared to older biologics (adalimumab, etanercept, and ustekinumab) in reaching 90% or 100% skin clearance, as measured with the Psoriasis Area Severity Index. The risk of side effects was similar between the newer and older biologics. Go to:
13 lut 2019 · This guideline will cover the use of biologic agents in the treatment of psoriasis in adults; psoriasis in the pediatric population will be covered in the “Guidelines of care for the management and treatment of pediatric psoriasis” guideline.
